Gesine Meyer

Dr. Gesine Meyer

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2013 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
GMGesine Meyer
Gesine Meyer
AHA. Hackemann
A. Hackemann
MPM. Penna-Martinez
M. Penna-Martinez
KBK. Badenhoop
K. Badenhoop
Several studies have shown a reduced quality of life in patients with Addison’s disease, but little is known about the potential influences. We determined the quality of life in 200 patients with Addison’s disease using an Addison’s disease-specific quality-of-life questionnaire. Data about first symptoms, time to diagnosis and current medication were collected by questionnaires. With increasing latency between first symptoms and diagnosis of adrenal insufficiency, the quality of life decreased in highly significant manner (p<0.001). Age at manifestation correlated negatively with quality of life (p=0.01). Significantly lower scores were observed in females versus males (141 vs. 159, p<0.001). Quality of life decreased significantly with increasing autoimmune comorbidity (p=0.01). Coeliac disease (p=0.05), atrophic gastritis (p=0.01) and primary ovarian failure (p=0.01) were highly correlated with reduced scores. Quality of life was significantly lower in female patients and in those with manifestation at older ages. With more autoimmune comorbidities, the quality of life scores dropped. The most important factor, however, was latency between first symptoms and diagnosis that affected patients’ quality of life even years after manifestation of the disease. These results confirm and extend previous observations and emphasize the importance of a timely diagnosis. Therefore, medical awareness for this rare but easily treatable disorder needs to be sharpened.

10 March 2016 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
GMGesine Meyer
Gesine Meyer
KBKlaus Badenhoop
Klaus Badenhoop
RLRoland Linder
Roland Linder

1 February 2020 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
GMGesine Meyer
Gesine Meyer
MMMoritz Mayer
Moritz Mayer
AMAntonia Mondorf
Antonia Mondorf
AFAnna Katharina Flügel
Anna Katharina Flügel
EHEva Herrmann
Eva Herrmann
JBJoerg Bojunga
Joerg Bojunga
Objective: Hormone treatment is an important part of gender reassignment therapy in gender dysphoria. Previous data about efficacy and safety are commonly based on small cohorts or they comprise former cohorts under meanwhile obsolete therapy regimes. Our objective was to investigate these topics in a large cohort of individuals under guideline-based treatment. Design/methods: Cohort study of medical files of n = 155 male-to-female (transwomen) and n = 233 female-to-male transgender persons (transmen) of an Endocrine outpatient clinic between 2009 and 2017. Results: Median time to reach amenorrhoea in transmen under testosterone monotherapy was 3 months, regardless of whether testosterone undecanoat or gel was used. Transmen with higher levels of hemoglobin 3–4 months after onset of GAHT had a greater chance to reach amenorrhea early, whereas testosterone levels showed no significant correlation (hemoglobin: HR: 1.639; 95% CI: 1.036–2.591, P = 0.035; testosterone: HR: 0.999; 95% CI: 0.998–1.001, P = 0.490). Estradiol levels (ρ −0.117; P = 0.316) had no significant influence on breast development in transwomen. Testosterone levels (ρ −0.398; P < 0.001) and FAI (ρ 0.346; P = 0.004) were significantly negatively correlated with reached Tanner stage. Liver values and blood lipids showed an alignment to reference range of the required sex in both groups. Relevant elevations of liver values were rare (2.44% in transmen, 4.23% in transwomen) and transient in most cases. Most relevant side effects were acne (44.8%), respectively erythrocytosis (up to 5.6%) in transmen and venous thrombembolism (1.9%) in transwomen. Conclusions: Gender-affirming hormone therapy in accordance with current clinical practice guidelines is efficient and safe.

4 April 2018 in Clinical Endocrinology
Verified
Journal Article
Open access
PDF file
SBStephanie Burger‐Stritt
Stephanie Burger‐Stritt
PKPavel Kardonski
Pavel Kardonski
APAlina Pulzer
Alina Pulzer
GMGesine Meyer
Gesine Meyer
MQMarcus Quinkler
Marcus Quinkler
SHStefanie Hahner
Stefanie Hahner
Summary: Objective: To evaluate the management of adrenal emergencies (AE) requiring parenteral glucocorticoid (GC) treatment in patients with chronic adrenal insufficiency (AI).Design: Prospective, multicentre, questionnaire‐based study.Patients and measurements: Participating patients (n = 150) with chronic AI were provided with a questionnaire on the management of emergency situations, which had to be completed and sent back in case of an AE. In addition, patients were contacted by phone on a regular basis.Results: Fifty‐nine AE in 39 patients were documented. The time interval from contact to arrival of a medical professional was 20 minutes (1‐240). In total, in 43 AE, patients received parenteral GC by a medical professional. The time interval between showing the emergency card and GC injection by a medical professional was 60 minutes (5‐360). A total of 26 patients administered GC by self‐injection. The time from the beginning of symptoms to GC injection was significantly shorter in case of self‐injection (self‐injection vs injection by medical professional; 85 minutes [20‐280] vs 232.5 minutes [1‐3135]; P < .001). After self‐injection, 62% of the patients were treated outpatient, compared to 27% of the patients after exclusive injection by a medical professional (P = .008). To improve the emergency management, most of the patients (84%) indicated a need for an easier way of self‐injection.Conclusion: While management of AE by both patients and medical professionals still shows high variability, patients profit from the option of self‐injection. Patient care, including education of patients and health‐professionals, as well as the way of GC administration, needs further optimization.

1 May 2012 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
GMGesine Meyer
Gesine Meyer
AHAnnika Hackemann
Annika Hackemann
JRJuergen Reusch
Juergen Reusch
KBKlaus Badenhoop
Klaus Badenhoop
Background: Hypoglycemia can be a symptom in patients with Addison's disease. The common regimen of replacement therapy with oral glucocorticoids results in unphysiological low cortisol levels in the early morning, the time of highest insulin sensitivity. Therefore patients with Addison's disease are at risk for unrecognized and potentially severe nocturnal hypoglycemia also because of a disturbed counterregulatory function. Use of a continuous glucose monitoring system (CGMS) could help to adjust hydrocortisone treatment and to avoid nocturnal hypoglycemia in these patients. Methods: Thirteen patients with Addison's disease were screened for hypoglycemia wearing a CGMS for 3–5 days. Results: In one patient we identified a hypoglycemic episode at 3:45 a.m. with a blood glucose level of 46 mg/dL, clearly beneath the 95% tolerance interval of minimal glucose levels between 2 and 4 a.m. (53.84 mg/dL). After the hydrocortisone replacement scheme was changed, the minimum blood glucose level between 2 and 4 a.m. normalized to 87 mg/dL. Conclusions: Continuous glucose monitoring can detect nocturnal hypoglycemia in patients with primary adrenal insufficiency and hence prevent in these patients an impaired quality of life and even serious adverse effects.

31 January 2018 in Endocrine
Verified
Journal Article
Closed access
PDF file
GMGesine Meyer
Gesine Meyer
MKMaike Koch
Maike Koch
EHEva Herrmann
Eva Herrmann
JBJörg Bojunga
Jörg Bojunga
KBKlaus Badenhoop
Klaus Badenhoop